Public Joint-Stock Company "Pharmsynthez" reported earnings results for the half year ended June 30, 2021. For the half year, the company reported sales was RUB 221.88 million compared to RUB 142.22 million a year ago. Net loss was RUB 252.41 million compared to RUB 107.55 million a year ago. Basic loss per share from continuing operations was RUB 0.84 compared to RUB 0.36 a year ago. Diluted loss per share from continuing operations was RUB 0.84 compared to RUB 0.36 a year ago.